The Motley Fool··Prosper Junior BakinyNovo Nordisk's Rebound: Sustainable Recovery or False Dawn?
$NVO rebounds 60% on strong Q1 results and oral Wegovy adoption, but faces intense competition from $LLY. Next-gen pipeline offers growth options; reasonable valuation at 13.6x earnings.
LLYNVOZepboundWegovy